The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer
- PMID: 20299079
- PMCID: PMC3654386
- DOI: 10.1016/j.urology.2009.11.076
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer
Abstract
Objectives: To evaluate the prognostic significance of the total number of lymph nodes obtained at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence.
Methods: Between 1989 and 2006, a total of 628 patients underwent PC-RPLND and were found to have either fibrosis or teratoma. After Institutional Review Board approval, complete clinical and pathologic data were obtained from our prospective testis cancer surgical database. A Cox proportional hazards regression model was constructed to evaluate the association of the total number of lymph nodes obtained at PC-RPLND on disease recurrence.
Results: On pathologic evaluation, 248 (57%) patients had fibrosis and 184 (43%) patients had teratoma. The median number of lymph nodes resected was 25 (interquartile range, 15-37). On multivariable analysis, increasing postchemotherapy nodal size and decreasing lymph node counts were significant predictors of disease recurrence (P=.01, .04, respectively). For patients with 10 nodes removed, the predicted 2-year relapse free probability was 90%, compared with 97% when 50 nodes were removed.
Conclusions: Our data suggest that the total number of lymph nodes removed and analyzed is an independent predictor of disease recurrence after PC-RPLND. This has implications both for the urologist to assure completeness of resection and for the pathologist to meticulously assess the pathologic specimens.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.J Clin Oncol. 2007 Mar 20;25(9):1033-7. doi: 10.1200/JCO.2005.05.4791. Epub 2007 Jan 29. J Clin Oncol. 2007. PMID: 17261854
-
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.Urology. 2012 Jan;79(1):156-9. doi: 10.1016/j.urology.2011.09.038. Urology. 2012. PMID: 22202548
-
Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection.Urology. 2015 Nov;86(5):981-4. doi: 10.1016/j.urology.2015.06.004. Epub 2015 Jul 29. Urology. 2015. PMID: 26232690
-
Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.Eur Urol. 2008 Feb;53(2):260-72. doi: 10.1016/j.eururo.2007.10.033. Epub 2007 Oct 31. Eur Urol. 2008. PMID: 18045770 Review.
-
Contemporary management of postchemotherapy testis cancer.Eur Urol. 2012 Nov;62(5):867-76. doi: 10.1016/j.eururo.2012.08.014. Epub 2012 Aug 20. Eur Urol. 2012. PMID: 22938868 Review.
Cited by
-
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.J Urol. 2014 Aug;192(2):415-9. doi: 10.1016/j.juro.2014.01.104. Epub 2014 Feb 8. J Urol. 2014. PMID: 24518791 Free PMC article.
-
Retroperitoneal lymph node dissection: an update in testicular malignancies.Clin Transl Oncol. 2017 Jul;19(7):793-798. doi: 10.1007/s12094-017-1622-5. Epub 2017 Feb 1. Clin Transl Oncol. 2017. PMID: 28150168 Review.
-
Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.World J Urol. 2021 Jun;39(6):1969-1976. doi: 10.1007/s00345-020-03437-z. Epub 2020 Sep 21. World J Urol. 2021. PMID: 32955662 Free PMC article.
-
Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience.J Robot Surg. 2019 Dec;13(6):747-756. doi: 10.1007/s11701-018-00903-0. Epub 2019 Jan 17. J Robot Surg. 2019. PMID: 30656537
-
Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection.Front Surg. 2019 Jan 17;5:80. doi: 10.3389/fsurg.2018.00080. eCollection 2018. Front Surg. 2019. PMID: 30705885 Free PMC article.
References
-
- Bosl G, Bajorin D, Sheinfeld J, Motzer R, Chaganti R. Cancer of the Testis. In: Devita Y, Hellman S, Rosenberg S, editors. Cancer: Principles and practice of oncology. Philidelphia: JB Lippincott; 2000. pp. 1491–1518.
-
- Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8:1683–1694. - PubMed
-
- Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25:5603–5608. - PubMed
-
- Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006;24:3570–3575. - PubMed
-
- Touijer K, Rabbani F, Otero JR, Secin FP, Eastham JA, Scardino PT, Guillonneau B. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% J Urol. 2007;178:120–124. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical